Methods and compositions for treating hypoglycemic disorders

• US 9,821,031 B2
• Filed: 01/08/2008
• Issued: 11/21/2017
• Est. Priority Date: 01/08/2007
• Status: Active Grant

• Current Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation), Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation), Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Stoffers, Doris, De Leon, Diva D., Stanley, Charles
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): NIEBAUER, RONALD T
• Application Number:
  US12/522,274
• Publication Number:
  US 20100190700A1
• Time in Patent Office: 3,605 Days
• Field of Search: None
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof.

Claims

1. A method of treating a subject with post-prandial hypoglycemia, comprising the step of subcutaneously administering to said subject an antagonist of the Glucagon Like Peptide-1(GLP-1) receptor, wherein said GLP-1-antagonist is a peptide, wherein the amino acid sequence of the peptide is the amino acid sequence set forth in SEQ ID NO:

1, and wherein said post-prandial hypoglycemia is associated with a gastric surgery.

2. The method of claim 1, wherein said post-prandial hypoglycemia is associated with a Nissen fundoplication.

3. The method of claim 1, wherein said post-prandial hypoglycemia is associated with a gastric-bypass surgery.

4. The method of claim 1, wherein the subject is a pediatric subject.

5. The method of claim 1, wherein the antagonist is administered at a dosage from 20 nmol/kg/day to 2000 nmol/kg/day.

6. The method of claim 1, wherein the antagonist is administered at a dosage from 20 nmol/kg/day to 300 nmol/kg/day.

7. The method of claim 1, wherein the antagonist is administered at a dosage of 100 nmol/kg/day.

8. The method of claim 1, wherein the antagonist is administered at a dosage of 200 nmol/kg/day.

9. The method of claim 1, wherein the antagonist is administered at a dosage of 300 nmol/kg/day.